Leadership
Lincoln Pharmaceuticals Quality Assurance Head Pradeep Kumar Yadav Resigns After One Month
By News Desk ·
Key takeaways
- Pradeep Kumar Yadav resigned as Senior General Manager of Quality Assurance at Lincoln Pharmaceuticals effective October 17, 2026, citing personal reasons.
- Lincoln Pharmaceuticals filed the disclosure under Regulation 30 of SEBI LODR Regulations with NSE and BSE, and no replacement has been appointed.
- Yadav was appointed to the same role on September 24, 2026, when the company accepted Manoj Rai's resignation from the position.
Lincoln Pharmaceuticals Ltd. announced that Pradeep Kumar Yadav resigned as Senior General Manager of Quality Assurance, effective October 17, 2026, after close of business hours, citing personal reasons. The company filed the disclosure with the National Stock Exchange of India Limited and BSE Limited, ScanX reported. No replacement has been appointed.
Yadav's Resignation and the Regulatory Filing
Lincoln Pharmaceuticals Ltd., India said the filing was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, according to akta.pro company records. The disclosure confirmed that Yadav served as a designated Senior Management Personnel before his cessation. The resignation was accepted to be relieved on October 17, 2026, after close of business hours.
The company disclosed that a copy of the resignation letter setting out the reasons for the change was enclosed with the filing. The disclosure noted that brief profile details and director relationship disclosures were not applicable as this was a resignation rather than an appointment. The filing cited personal reasons as the cause for the resignation.
Lincoln Pharmaceuticals' Quality Assurance Leadership Change
Yadav was appointed as Senior General Manager, Quality Assurance, effective September 24, 2026, and the company accepted Manoj Rai's resignation from the same role, according to ScanX. The September 24, 2026 appointment and the October 17, 2026 cessation both concerned the same position.
Lincoln Pharmaceuticals' Recent Financial and Operational Moves
Lincoln Pharmaceuticals declared a final dividend of ₹1.80 per share for FY26, approved at its September 30, 2026 Annual General Meeting, ScanX reported. The dividend and financial statements passed with 100% assent, while director reappointments faced approximately 4.5% dissent.
The company proposed the ₹1.80 per share final dividend on September 5, 2026, an 18% payout on the ₹10 face value, with the 32nd AGM scheduled for September 30, 2026 and a record date of September 11, 2026, according to ScanX. On August 29, 2026, Lincoln Pharmaceuticals announced the AGM would be held via video conferencing with the record date set for September 11, 2026, ScanX reported.